Eton Pharmaceuticals (ETON) Net Income towards Common Stockholders (2018 - 2026)

Eton Pharmaceuticals has reported Net Income towards Common Stockholders for 8 years, with the latest figure at $1.7 million in Q4 2025.

• Quarterly Net Income towards Common Stockholders rose 383.61% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.4 million (down 14.78% YoY) and the FY2025 annual result came in at -$4.4 million, down 14.78% from the prior year.
• Net Income towards Common Stockholders grew to $1.7 million in Q4 2025 per ETON's latest filing, from -$1.9 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $5.1 million in Q1 2021 and troughed at -$6.1 million in Q3 2021.
• A 5-year average of -$891850.0 and a median of -$1.6 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders soared 392.62% in 2023, then tumbled 407.34% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at $1.0 million in 2021, then jumped by 170.07% to $2.8 million in 2022, then plunged by 166.43% to -$1.9 million in 2023, then soared by 67.92% to -$598000.0 in 2024, then surged by 383.61% to $1.7 million in 2025.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $1.7 million, -$1.9 million, and -$2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.